about
Translation initiator EIF4G1 mutations in familial Parkinson diseaseAlpha-synuclein locus duplication as a cause of familial Parkinson's diseasePopulation-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium.Alpha-synuclein repeat variants and survival in Parkinson's diseaseIndependent and joint effects of the MAPT and SNCA genes in Parkinson disease.The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain.Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's diseaseAssociation of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.Association study of three polymorphisms of TGF-beta1 gene with Alzheimer's disease.Characterization of DCTN1 genetic variability in neurodegeneration.Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.Genomic investigation of alpha-synuclein multiplication and parkinsonism.Deregulation of protein translation control, a potential game-changing hypothesis for Parkinson's disease pathogenesis.Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.Is there a role for ghrelin in central dopaminergic systems? Focus on nigrostriatal and mesocorticolimbic pathways.LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease.Xenopus laevis as a Model to Identify Translation Impairment.ATXN2 a culprit with multiple facets.Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease.Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease.Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms.Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation.SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes.NADPH oxidases in Parkinson's disease: a systematic review.PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2.A polymorphism in the angiotensin 1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer's disease.Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease.UCHL1 is a Parkinson's disease susceptibility gene.Association at LRP gene locus with sporadic late-onset Alzheimer's disease.CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation.Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study.A polymorphism within intron 11 of the tau gene is not increased in frequency in patients with sporadic Alzheimer's disease, nor does it influence the extent of tau pathology in the brain.Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease.Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease.Is the LDL receptor-related protein involved in Alzheimer's disease?Alzheimer's disease: A beta or ApoE amyloidosis?
P50
Q28247679-75C3CD21-0584-44F3-8D18-574EC2145399Q29614762-6BCBC2DB-2C31-4B19-94AD-72242ADC968BQ33939245-2A828627-2C85-4169-B60A-E84F3C0C50EAQ34231155-10379BC7-D695-443E-B1F2-1CDD4C7C70F3Q34860779-5CE9F2BF-E39E-4272-8208-3AEF423E4FD8Q35437516-C30560DE-5559-414E-8592-B35A79259DB1Q35442817-78C0A0F9-969F-4186-B980-7F5F8DDBCA9EQ35525896-D022ACD1-8055-4452-9EDD-BEF7DFBA60C5Q35559960-00859E39-8946-49D1-BDBE-DF20CFAF25EEQ37216156-3D8BE7B5-B502-4ACA-9542-922648F4753FQ37312762-C15E649F-FFE6-4F16-BD21-4DC2B615336FQ37362778-7B9D9F8D-0B73-42DE-97A3-DE7383AB09FCQ38532397-05048B70-FF80-4DE9-BCFB-BE3F696C3F55Q38619109-F6E8CBA6-660B-459D-B1B6-DD50BE7E7F50Q38765856-323A1700-1B99-4498-AA7E-744101483301Q38814476-0023A7F2-65F1-4D6E-9BC5-0FB244E35B87Q39028450-99B04D87-509E-4E37-A283-25CB3F0891E1Q39137378-64C1A603-D230-408D-9046-E7EAEDEB41F6Q39725780-B616060F-7E95-421B-8958-2DCF289DB610Q41686100-188843C4-3E29-42B3-9B26-352FB1733891Q42338750-6DED2253-3D09-4CEA-B717-E28549A1172FQ42605069-CEC3AD90-C46D-419A-8B25-C1E14CC8B27FQ42629781-530C8546-151E-4C25-964A-A00636116DADQ43484059-27B4C4AC-9E86-4040-ABD8-4C8D91D36E19Q45366757-442E50EC-C970-4EFC-8F3B-4141E296A865Q45941471-57EDF591-0BC0-4584-81E7-AB781B58E534Q46262582-66620B38-5254-47BF-8C6B-60EC45F4CC34Q47222316-802F0498-B36C-44E2-8496-7FFB0A6317F1Q47293922-3F9DBA1D-4D98-493B-8042-054129EE6D7EQ47354992-F8EE7EC1-AD0B-4F19-87C3-30AF70E4BDEEQ47866612-883FB8AE-93D2-42A9-9F7E-5DF0B9DD5FF3Q47943398-0B7351E9-1F76-4981-92BC-68882BF0B0CAQ48019775-DD3EAC75-B303-4AF1-8B45-9CE71CA070D0Q48192270-7E360BC5-BDBD-4630-ADFD-A2262D450908Q48422898-E66F9911-D2D3-442E-8A63-833C5A5B49BDQ48616835-669B5272-C4F1-4960-B92B-D365F3298797Q48791581-4BED35B2-9D63-4ABD-BADD-35C806824487Q48878851-9F3878D4-218D-4410-835C-6A3F08A9C4B3Q49085133-4563C363-8F9A-4E24-888C-ED4257681601Q53200746-7D5BB33E-556C-416C-BFD6-5C49F7DF588F
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-6416-6526
@en
name
Marie-Christine Chartier-Harlin
@ast
Marie-Christine Chartier-Harlin
@en
Marie-Christine Chartier-Harlin
@es
Marie-Christine Chartier-Harlin
@nl
type
label
Marie-Christine Chartier-Harlin
@ast
Marie-Christine Chartier-Harlin
@en
Marie-Christine Chartier-Harlin
@es
Marie-Christine Chartier-Harlin
@nl
altLabel
Chartier-Harlin MC
@en
marie-christine chartier-harlin
@en
prefLabel
Marie-Christine Chartier-Harlin
@ast
Marie-Christine Chartier-Harlin
@en
Marie-Christine Chartier-Harlin
@es
Marie-Christine Chartier-Harlin
@nl
P1053
L-4527-2018
P106
P21
P31
P4012
P496
0000-0001-6416-6526